COMMUNIQUÉS West-GlobeNewswire

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
05/11/2025
Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of [...]
Altimmune to Participate in Two Upcoming Investor Conferences
05/11/2025
GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, [...]
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
05/11/2025
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) [...]
Crescent Biopharma to Present at November Investor Conferences
05/11/2025
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer [...]
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
05/11/2025
Webcast scheduled for Monday, November 10 at 12:00 pm EST REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on [...]
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
05/11/2025
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of [...]
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
05/11/2025
ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week [...]
Telix to Participate in UBS and Jefferies Global Healthcare Conferences
05/11/2025
MELBOURNE, Australia and INDIANAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming UBS Global Healthcare Conference in Palm Beach, FL [...]
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
05/11/2025
DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. [...]
Immuron IMM-529 IND approved by FDA
05/11/2025
Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceed FDA assigned an IND number (032095) for the IMM-529 [...]
RadNet Expands Comprehensive Remote Scanning Offering with Acquisition of Alpha RT’s Assets
05/11/2025
RadNet subsidiary DeepHealth to commercialize a robust end-to-end remote-imaging offering featuring both TechLive™ remote scanning technology and Alpha RT’s MRI staffing services and training programs LOS ANGELES, Nov. [...]
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
05/11/2025
Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgery Experiencing strong commercial traction in UK as first market [...]
Maple acquires Beyond ADHD to expand responsible ADHD and mental health care across Canada
05/11/2025
Acquisition strengthens access to clinically led virtual ADHD and mental health programs nationwide TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Maple, Canada’s leading virtual care company, today announced the [...]
Oculis to Participate in Upcoming November Investor Conferences
05/11/2025
ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical [...]
Oculis to Participate in Upcoming November Investor Conferences
05/11/2025
ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical [...]
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
05/11/2025
COPENHAGEN, Denmark, November 5, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.92% [...]
TME Pharma advances its new investment strategy and signs LOI with German resources company
05/11/2025
TME Pharma advances its new investment strategy and signs LOI with German resources company A further step toward investment diversification into potential cash-flow–generating assets A potential strategic investment in [...]
TME PHARMA POURSUIT SA NOUVELLE STRATÉGIE D'INVESTISSEMENT ET SIGNE UNE LETTRE D'INTENTION AVEC UNE SOCIÉTÉ ALLEMANDE SPÉCIALISÉE DANS LES RESSOURCES NATURELLES
05/11/2025
TME PHARMA POURSUIT SA NOUVELLE STRATÉGIE D'INVESTISSEMENT ET SIGNE UNE LETTRE D'INTENTION AVEC UNE SOCIÉTÉ ALLEMANDE SPÉCIALISÉE DANS LES RESSOURCES NATURELLES Nouvelle étape vers la diversification des investissements [...]
AVEROA Receives UK MHRA Approval for XOANACYL®, an Oral Therapy Targeting Key Complications of Chronic Kidney Disease (CKD)
05/11/2025
The MHRA ( Medicines and Healthcare products Regulatory Agency) granted UK Marketing Authorisation for XOANACYL via the International Recognition Procedure (Route B) recognising its prior EU approval (June 2025) [...]

Pages